Veteran private-equity and healthcare operator focused on scaling specialty pharma and services businesses across North America and Europe. Alan Rosenfield brings corporate-development and M&A experience, advising boards on commercialization strategy, licensing and carve-outs while overseeing portfolio-company performance and capital allocation. Known for operational rigor, deal execution and post-acquisition integration, frequently active as an investor, board director and interim CRO/CBO in growth-stage healthcare companies.
Veteran private-equity and healthcare operator focused on scaling specialty pharma and services businesses across North America and Europe. Alan Rosenfield brings corporate-development and M&A experience, advising boards on commercialization strategy, licensing and carve-outs while overseeing portfolio-company performance and capital allocation. Known for operational rigor, deal execution and post-acquisition integration, frequently active as an investor, board director and interim CRO/CBO in growth-stage healthcare companies.
Operates a hands-on, value‑creation approach focused on mid-market specialty pharma and healthcare services in North America and Europe. Prioritizes platform investments and buy-and-build roll-ups where operational playbooks, commercialization acceleration, licensing optimization and disciplined capital allocation drive EBITDA expansion. Investment style blends private‑equity control or minority-stewardship with active board roles and interim commercial leadership, targeting scalable revenue growth and margin improvement over a medium-term (3–5 year) hold period.
Operates a hands-on, value‑creation approach focused on mid-market specialty pharma and healthcare services in North America and Europe. Prioritizes platform investments and buy-and-build roll-ups where operational playbooks, commercialization acceleration, licensing optimization and disciplined capital allocation drive EBITDA expansion. Investment style blends private‑equity control or minority-stewardship with active board roles and interim commercial leadership, targeting scalable revenue growth and margin improvement over a medium-term (3–5 year) hold period.
| Trades 1585 | Longs Won 1152/1585 72% | Profit Factor 7.65 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $607,753.54 |
| Average Win $127,812.41 | Best Trade (Oct 15) $17.34M | Sharpe Ratio -9.94 |
| Average Loss -$44,479.26 | Worst Trade (Sep 30) -$3.06M | Z-Score 9.37 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3w 2d | Expectancy $80,744.72 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 8,696 | 7,826 | 6,957 | 6,087 | 5,217 | 4,348 | 3,478 | 2,609 | 1,739 | 870 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 68,795 | $13.44M | $23.79M | - | $10.36M | 77.08% | +1.13% |
ABBV AbbVie Inc. | 22,863 | $4.81M | $6.54M | - | $1.73M | 36.01% | +0.946% |
ABT Abbott Laboratories | 13,560 | $1.23M | $1.42M | - | $193,094.8 | 15.69% | +0.287% |
AFL Aflac Inc. | 5,968 | $492,360.47 | $712,728.4 | - | $220,367.93 | 44.76% | +1.165% |
AGX Argan Inc. | 287 | $229,184 | $102,631.2 | - | -$126,552.8 | -55.22% | -2.604% |
AMAT Applied Materials, Inc. | 4,828 | $900,001.42 | $2.01M | - | $1.11M | 123.57% | -3.079% |
AMGN Amgen Inc. | 6,712 | $2.15M | $2.94M | - | $793,009.38 | 36.94% | +0.909% |
AMT American Tower Corporation | 4,707 | $1.02M | $866,841.12 | - | -$150,909.14 | -14.83% | +1.544% |
AMZN Amazon.com Inc | 54,717 | $8.9M | $13.9M | - | $5M | 56.19% | -0.302% |
ANET Arista Networks, Inc. | 21,270 | $2.65M | $3.83M | - | $1.18M | 44.45% | -2.956% |
APH Amphenol Corporation | 7,372 | $228,177.43 | $594,514.94 | - | $366,337.51 | 160.55% | -1.037% |
AVGO Broadcom Inc. | 8,277 | $1.13M | $2.78M | - | $1.65M | 146.11% | -2.39% |
BA Boeing Company | 5,601 | $1.2M | $1.07M | - | -$133,547.47 | -11.12% | +1.003% |
BAC Bank of America Corporation | 49,675 | $2.27M | $2.61M | - | $341,173.6 | 15.05% | +1.538% |
BHP BHP Group Ltd. | 7,353 | $451,727.44 | $621,990.27 | - | $170,262.83 | 37.69% | +2.039% |
BIL SPDR Bloomberg 1-3 Month T-Bill ETF | 21,894 | $2.01M | $2M | - | -$1,950.96 | -0.1% | +0.014% |
BKR Baker Hughes Company | 8,522 | $292,035.46 | $474,164.08 | - | $182,128.62 | 62.37% | +2.279% |
BLK BlackRock, Inc. | 2,974 | $2.84M | $3.39M | - | $548,782.61 | 19.3% | +1.78% |
BND Vanguard Total Bond Market Index Fund | 12,989 | $953,174.58 | $920,920.1 | - | -$32,254.48 | -3.38% | +0.127% |
BNDX Vanguard Total International Bond ETF | 10,510 | $516,723.32 | $495,967.95 | - | -$20,755.37 | -4.02% | -0.042% |